This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Fasenra
  • /
  • Efficacy and Safety Study of Benralizumab in Patie...
Clinical trial

Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)

Read time: 3 mins
Last updated:7th Sep 2017
Identifier: NCT03186209

Brief Summary:
This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma exacerbations and uncontrolled asthma receiving medium to high-dose inhaled corticosteroid plus long-acting β2-agonist (ICS-LABA) with or without oral corticosteroids and additional asthma controllers.

Detailed Description:
Approximately 666 patients will be randomised. Patients will be stratified by country/region, age group (adult or adolescent), and peripheral blood eosinophil count at time of Visit 1 (<300 or ≥300 cells/μL).All the patients will be randomised to either placebo or benralizumab (1:1 ratio) for a 48-weeks treatment, every 4 weeks for the first 3 doses and then every 8 weeks thereafter.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 666 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma.
Actual Study Start Date: September 7, 2017
Estimated Primary Completion Date: February 26, 2021
Estimated Study Completion Date: February 26, 2021

Arms:
- Experimental:
Benralizumab
- Placebo Comparator: Placebo

Category Value
Date last updated at source 2019-06-03
Study type(s) Interventional
Expected enrolment 666
Study start date 2017-09-07
Estimated primary completion date 2021-02-26

View full details